Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

Clinical trials

Trial design and trial results are where value claims start. This coverage follows pivotal readouts, trial methodology and the evidentiary standards regulators and HTA bodies apply to them.

440 articles in this topic.

Articles in this category

Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion

11/17/2026

Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion

The three-month dapivirine vaginal ring has received a positive EMA scientific opinion, with the ring replaced four times per year. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay

11/17/2026

Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay

The CHMP has recommended povorcitinib for hidradenitis suppurativa as Povofortay, a JAK1 inhibitor for adults who responded inadequately to, or are intolerant or contraindicated to, anti-TNF therapy.
Read Article →
FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap

11/17/2026

FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap

FDA rejects ivonescimab lung cancer treatment: the trial slowed progression, but the overall survival benefit did not reach statistical significance.
Read Article →
EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows

11/17/2026

EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows

EMA recommends Gazyvaro for systemic lupus erythematosus after a 303-patient trial showed 76.7% response on add-on therapy versus 53.5% on placebo.
Read Article →
CHMP November 2026 Recommends Seven New Medicines for Approval

11/16/2026

CHMP November 2026 Recommends Seven New Medicines for Approval

EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

11/16/2026

Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

The CHMP recommended granting a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess
Read Article →
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024

11/13/2026

Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024

Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess
Read Article →
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa

11/12/2026

Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa

Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess
Read Article →
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

11/10/2026

Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess
Read Article →
M72 tuberculosis vaccine approval in Indonesia: BPOM weighs a fast track

11/6/2026

M72 tuberculosis vaccine approval in Indonesia: BPOM weighs a fast track

BPOM is drafting a conditional approval route for the M72 TB vaccine and a joint review with the European Medicines Agency, ahead of Phase 3 results.
Read Article →
Truqap prostate cancer withdrawal: AstraZeneca pulls EU bid

11/4/2026

Truqap prostate cancer withdrawal: AstraZeneca pulls EU bid

"Truqap prostate cancer withdrawal: AstraZeneca pulled its EU bid for newly diagnosed use after EMA raised benefit-risk concerns." #SyenzaNews #MarketAccess
Read Article →
FDA Potency Assurance Guidance: What It Asks of Cell and Gene Therapy Makers

11/3/2026

FDA Potency Assurance Guidance: What It Asks of Cell and Gene Therapy Makers

FDA has finalized its potency assurance guidance for cell and gene therapy products. It covers lot-release testing, potency assays, acceptance criteria and how sponsors should build a strategy from the IND stage onward. #SyenzaNews #CellAndGeneTherapy #FDA
Read Article →

Related topics